A heterozygous loss-of-function mutation of the PTEN gene, one of the tumor suppressor genes, causes a wide variety of disorders, ranging from macrocephaly/autism syndrome to PTEN hamartoma tumor syndrome, including Cowden disease that causes thyroid and breast cancer mainly in the adolescence and young adult generation. An 8-month-old male infant with simple macrocephaly developed a café-au-lait spot and two subcutaneous tumors at the age of 1 year. One of the tumors developed rapidly was resected at the age of 1 year and 9 months and identified as benign lipoma. From the age of 2 years, the patient often threw a tantrum. At the age of 2 years and 9 months, a pathogenic germline mutation was identified in the PTEN gene (NM_000314.7), c.195C>A, p.Y65 * in the form of a heterozygous germline variant. Developmental delay was noted but no tumors were found in the thyroid gland and breasts. Immunohistochemistry for PTEN in the resected lipoma demonstrated that the PTEN expression pattern was similar to that in a subcutaneous adipose tissue from a normal subject, suggesting that two-hit was not likely involved in the rapid growth of this lipoma. At the age of 5 years, the patient was diagnosed with autism spectrum disorders with moderate developmental delay. A long-term follow-up is underway to examine developmental changes in psychomotor disorders and possible tumor formation.
Introduction
The phosphatase and tensin homolog (PTEN) gene is one of the tumor suppressor genes (1) located in chromosome 10q23.31, encoding 403 amino acids of 47166 Da protein.
Loss of heterozygosity and deletion of this gene was first reported in glioblastomas, and later in several malignant tumors (2) . PTEN germline mutations cause a wide variety of phenotypic diseases, such as macrocephaly/autism syndrome (OMIM #605309) usually noticed in infants and PTEN hamartoma tumor syndrome (PHTS, OMIM #601728). PHTS includes Cowden syndrome (CS, OMIM#158350) and Bannayan-Riley-Ruvalcaba syndrome (BR RS, OMIM#153480) (3) .
Macrocephaly/autism syndrome is an autosomal dominant disorder characterized by increased head circumference, abnormal facial features, and delayed psychomotor development resulting in autistic behavior or mental retardation (4) . Varga et al (5) reported that PTEN mutations were detected in 5 of 60 (8.3%) patients with autism spectrum disorder (ASD) and 6 of 49 (12.2%) patients with developmental delay and macrocephaly without ASD.
CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, and endometrium in young adults and adults. Arteriovenous malformation, multiple lipomas, and other soft-tissue tumors are also reported (3, 6) . Affected individuals usually develop macrocephaly, trichilemmomas, and papillomatous papules by late 20s. On the other hand, BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis (3) . For PHTS patients, 2019.2 NCCN guideline (7) recommends that tumor follow-up involves annual physical examination and thyroid ultrasound, with colonoscopy every 5 years beginning at age 35 or earlier based on family colon cancer history and kidney ultrasound every 1-2 years starting at age 40.
We found a de novo PTEN germline mutation in a male infant with macrocephaly and lipomas by using NGS analysis. A rapidly growing lipoma was resected and examined for PTEN by immunostaining, since there have been few reports on PTEN inactivation, two hits or one hit, in tumors in PHTS patients.
Case report
Patient. Male infant was born after 37 weeks gestation with 4,078 g (+2.7 SD) in weight, 52 cm (+1.4 SD) in height and 36 cm (+1.9 SD) in head circumference.
Family history: No physical abnormalities are apparent with the father, 37 years old, the mother, 33 years old and a sister, 3 years old.
Pregnancy history: Pregnancy progressed uneventfully. The delivery was through the vagina after induction.
Postnatal progress: No special findings in one-and four-month postnatal examinations. The infant showed roll-over at 6 months old, neck stabilization at 7 months old, and independent gait at 1 year and 5 months. He exhibited obsession and temper tantrum frequently after 2 years of age. Macrocephaly was pointed out when he was taken to a hospital for treatment of bronchitis at the age of 8 months. His height was then 70 cm (+2.8 SD), weight 8,845 g (+0.2 SD) and head circumference 48.5 cm (+2.8 SD). Brain MRI showed no abnormal signals in cerebral parenchyma (data not shown), indicating that his macrocephaly was a simple one. To elucidate the cause of macrocephaly, genetic testing was performed at the age of 1 year and 9 months under the informed consents of the parents.
At the age of one-year, two elastic soft subcutaneous tumors of 1-2 cm in diameter appeared in the abdomen and in the right side of the back. A café-au-lait spot of 2 cm in diameter was also found on the left side of the back. At the age of 1 year and 9 months, one tumor in the abdomen rapidly enlarged to 6x5 cm ( Fig. 1A) and was surgically removed. The removed tumor was soft and yellowish and macroscopically diagnosed as a lipoma.
At the age of 2 years and 9 months, the results of genetic testing were reported, and genetic counseling was performed. At this time, his height was 92 cm (+0.2 SD), weight 16 kg (+2.1 SD), and head circumference 55 cm (+3.7 SD). He showed a broad and projected forehead, a flat nasal root and low-set deformed auricles. A café-au-lait spot of 2x2.5 cm in size was present on the left back and subcutaneous tumors of 2x2 cm in the right back ( Fig. 1B) At the age of 3 years, follow-up brain MRI showed no abnormality in the cerebral white matter ( Fig. 1C and D) , except for the hypertrophied corpus callosum ( Fig. 1E ) and enlargement of the perivascular space ( Fig. 1F ), of which findings were consistent with simple macrocephaly.
At the age of 5 years, subcutaneous tumors in the back and the sole remained the same in size, and no newly developed tumors and café-au-lait spots were detected. He could not communicate normally and was diagnosed as ASD with moderate developmental delay.
Chromosomal analysis. Using peripheral blood, G-banding was performed.
Whole-exome sequencing and Sanger sequencing. DNA was extracted from peripheral blood of the patient and the parents and Whole exome sequencing was performed as previously described (9) . Regions suspected of containing pathological mutations were amplified by PCR and subjected to Sanger analysis (HGMD R Professional 2016.1).
Pathologic examination. The surgical specimen was fixed in formalin and embedded in a paraffin block. Sections cut from the block were stained with hematoxylin-eosin and with an immunoperoxidase method using anti-PTEN antibody (Dako/Agilent Technologies, Santa Clara, CA). Stained sections were examined under a light microscope. As a control, a subcutaneous fat containing skin sample obtained from a one-year-old male infant without CS were used anonymously.
Chromosomal analysis. Chromosomal analysis showed a normal karyotype.
Mutation of the PTEN gene.
In exon 3 of the PTEN (NM_000314.7), c.195C>A, p.Y65 * was found as a heterozygous germline variant in the patient. This mutation is considered as pathogenic, since the same mutation has been reported in one young adult female with macrocephaly/autism syndrome and one adult female with CS (10,11) (referred HGMD R Professional 2019.1). The predicting truncated PTEN protein with deletion of most of the C-terminal region is likely unstable leading to haploinsufficiency. This mutation is sporadic, since his parents did not carry the mutation. Based on these results, we diagnosed this patient with PTEN hamartoma tumor syndrome (PHTS). As this mutation was reported in a CS case, we performed ultrasound analysis of the thyroid and visual and palpitation inspection of breasts of the patient at 2 years and 10 months. No abnormalities were found in both tissues. Endoscopic examination of gastrointestinal tract was not performed because of his young age.
Pathologic findings of the subcutaneous tumor. The surgical specimen had a lobulated macroscopic appearance and was encapsulated with delicate fibrous veil ( Fig. 2A ). Histologically, it consisted of mature adipocytes, sparse blood vessels and thin collagen bundles (Fig. 2B) , and the diagnosis of lipoma was confirmed. Immunohistochemically, PTEN expression was observed in vessels in the control sample, as was expected ( Fig. 2C and D) . A few subcutaneous adipocytes were also stained. Similarly, in the lipoma tissue, vessels and a small number of neoplastic adipocytes were PTEN-positive ( Fig. 2E and F) . No obvious differences in PTEN expression, its distribution pattern and intensity, were detected between the lipoma tissue and the control tissue. Fig. 3 shows the position of the mutation in the PTEN protein (12) . Anti-PTEN antibody binds to a C-terminal region (13) . It is not possible to bind to the truncated protein due to the nonsense mutation in this patient (Fig. 3) .
Discussion
We found a PTEN mutation by NGS analysis in a male infant with macrocephaly. Brain MRI examination showed simple macrocephaly consistent with PTEN macrocephaly/autism syndrome reported by Vanderver et al (14) and Bhargava et al (15) . Table I shows 30 patients of <3 years of age with macrocephaly or autism spectrum in whom PTEN mutations were detected (4, 11, (14) (15) (16) (17) (18) (19) (20) . Clinical manifestations of these patients are presented in Table II . All cases showed developmental delay with 8 cases diagnosed as autism spectrum and 10 hypotonia.
Ten of 30 cases showed frontal bossing with 8 exhibiting café-au-lait spots and skin features, and 5 diagnosed with tumors and hamartomas, such as gastrointestinal polyps and cutaneous lipomas. Our case, an only in infant patient with macrocephaly/autism syndrome reported, suggests that the PTEN mutation detected is responsible for the syndrome.
All the 30 patients with macrocephaly in Table I showed no apparent genotype-phenotype correlation nor malignant tumors that are frequently observed in patients with CS. The risk of developing malignant tumors in later years is not clear, without follow-up data.
Tan et al (21) reported lifetime cancer risks of individuals with PTEN germline mutation listing a variety of cancers (breast, thyroid, endometrial, colorectal, renal cell, and melanoma) found in a cohort of 368 children and adults aged 0.4-83 years (median age; 39 years). The earliest age of cancer onset reported was 3 years for melanoma. In this paper, no follow-up analysis from childhood to adulthood was reported. Consequently, it is not clear as to how many infant macrocephaly cases with PTEN mutation developed to CS in adulthood. Smpokou et al (22) reported that, in the case of a 7-year-old patient with a thyroid cancer, clinical description would allow better formulation of clinical guidelines in children with PHTS. For infant patients with PTEN mutation, pediatricians have tendency to focus attention on macrocephaly, developmental delay or autism. It is therefore important to conduct follow-up assessment for both developmental problem and cancer incidence, and carry out lifelong and total medical management. On this basis, we conducted thyroid ultrasonography of our patient at the age of 2 years and 10 months, 4 years and 5 years of age and found no abnormality. Regarding gastrointestinal tract hamartomas, we did not perform endoscopic examination, since there have been no reports on the onset in childhood. We examined breasts only by inspection and palpation since the possibility of breast cancer was considered to be lower for male infant patients than female (23) .
Lipomas and a café-au-lait spot on the skin were also found in our case. Our immunohistochemical examination revealed that lipoma tissue and the skin tissue obtained from a control subject showed very similar PTEN expression. No obvious differences in PTEN expression were detected among them, suggesting that two-hit in the PTEN gene by loss of heterozygosity was unlikely even in the rapidly growing lipoma. A previous report shows that loss of heterozygosity of markers in endometrial cancer, glioblastoma, and breast cancer (13) . In our lipoma case, we are unable to do the immunohistochemical evaluation clearly.
To relieve psychosocial anxiety for PHTS patients and their parents with respect to cancer predisposition and developmental problems, genetic counseling is of need. Genetic counseling is also of use for family members who may feel at risk. Taken together, long-term follow-up plans for soft-tissue tumors, thyroid cancer, breast cancer and GI-hamartomas, as well as psychosocial problems are indispensable.
